Regorafenib

Category: Cancer



Regorafenib Overview

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had 2 US approvals for advanced cancers. Contents 1 Approvals and indications 1.1 Meta...

Read more Regorafenib Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Regorafenib

Recent Regorafenib Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Regorafenib
  • Tablet: 40mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Regorafenib or a similar ingredient: (1 result)

Related Regorafenib Topics:

regorafenib
quelle expérience avez vous de ce traitement ?...






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 21 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA